Pharsight

Clenpiq generic

Clenpiq is an oral solution drug owned by Ferring Pharms Inc. It contains Citric Acid, Magnesium Oxide, and Sodium Picosulfate as active ingredients. It was first authorized for market use on November 28, 2017, and holds a total of 3 patents, none of which have expired.

When will Clenpiq generic be available?

The generic versions of Clenpiq are expected to be released after June 26, 2034. This is because the latest patent for Clenpiq, with the title 'Liquid pharmaceutical composition', expires on June 26, 2034. Hence, the Clenpiq generic release should be possible after this date.

Clenpiq uses

Clenpiq is primarily used for cleansing the large intestine as a preparation for colonoscopy. Its active ingredients, Citric Acid, Magnesium Oxide, and Sodium Picosulfate, contribute to its effectiveness in this application.

Clenpiq patent expiration

Clenpiq holds three active patents, all with the title 'Liquid pharmaceutical composition'. The last of these patents is set to expire on June 26, 2034, after which the generics of Clenpiq can be released. Below are the details of the patent:

Clenpiq dosage

Want to ask something?